High-density lipoprotein subfractions and risk of coronary artery disease (original) (raw)

• Maron DJ: The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000, 86(suppl): 11L-14L.
  Article PubMed CAS Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al.: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62: 707–714.
  Article PubMed CAS Google Scholar
• Castelli WP: Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol 1988, 4(suppl A): 5A-10A.
  PubMed Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989, 79: 8–15.
  PubMed CAS Google Scholar
• Toth PP: Reverse cholesterol transport: high-density lipoprotein’s magnificent mile. Curr Atheroscler Rep 2003, 5: 386–393.
  PubMed Google Scholar
• Kwiterovich PO Jr: Lipoprotein heterogeneity: diagnostic and therapeutic implications. Am J Cardiol 2002, 90: 1i-10i.
  Article PubMed CAS Google Scholar
• Gotto AM Jr, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004, 43: 717–724.
  Article PubMed CAS Google Scholar
• Otvos JD, Jeyarajah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90(suppl): 22i-29i.
  Article PubMed CAS Google Scholar
• Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002, 48: 171–180.
  PubMed CAS Google Scholar
• Asztalos BF, Schaefer EJ: High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91(suppl): 12E-17E.
  Article PubMed CAS Google Scholar
• Vega GL, Grundy SM: Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996, 7: 209–216.
  Article PubMed CAS Google Scholar
• Reichl D, Miller NE: Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 1989, 9: 785–797.
  PubMed CAS Google Scholar
• Genest J Jr, Bard JM, Fruchart JC, et al.: Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb 1993, 13: 1728–1737.
  PubMed Google Scholar
• O’Brien T, Nguyen TT, Hallaway BJ, et al.: The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 1995, 15: 228–231.
  PubMed CAS Google Scholar
• Gotto AM Jr, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101: 477–484.
  PubMed CAS Google Scholar
• Bolibar I, von Eckardstein A, Assmann G, Thompson S: Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost. 2000, 84: 955–960.
  PubMed CAS Google Scholar
• Drexel H, Amann FW, Rentsch K, et al.: Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992, 70: 436–440.
  Article PubMed CAS Google Scholar
• Salonen JT, Salonen R, Seppänen K, et al.: HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation 1991, 84: 129–139.
  PubMed CAS Google Scholar
• Freedman DS, Otvos JD, Jeyarajah EJ, et al.: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18: 1046–1053.
  PubMed CAS Google Scholar
• Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002, 90: 89–94.
  Article PubMed CAS Google Scholar
• Robins SJ, Collins D, Wittes JT, et al., for the VA-HIT Study Group: Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 2001, 285: 1585–1591.
  Article PubMed CAS Google Scholar
• Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106: 453–458.
  PubMed CAS Google Scholar
• Garvey WT, Kwon S, Zheng D, et al.: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52: 453–462.
  Article PubMed CAS Google Scholar
• Ginsberg HN: Nonpharmacologic management of low levels of high-density lipoprotein cholesterol. Am J Cardiol 2000, 86: 41L-45L.
  Article PubMed CAS Google Scholar
• Ginsberg HN, Kris-Etherton P, Dennis B, et al., for the DELTA Research Group: Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998, 18: 441–449.
  PubMed CAS Google Scholar
• Sillanaukee P, Koivula T, Jokela H, et al.: Alcohol consumption and its relation to lipid-based cardiovascular risk factors among middle-aged women: the role of HDL3 cholesterol. Atherosclerosis 2000, 152: 503–510.
  Article PubMed CAS Google Scholar
• Kamanna VS, Kashyap ML: Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000, 2: 36–46.
  PubMed CAS Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106: 3143–3421.
  Google Scholar
• Morgan JM, Capuzzi DM, Baksh RI, et al.: Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003, 91: 1432–1436.
  Article PubMed CAS Google Scholar
• Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47: 1097–1104.
  Article PubMed CAS Google Scholar
• Crouse JR III, Frohlich J, Ose L, et al.: Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999, 83: 1476–1477.
  Article PubMed CAS Google Scholar
• Johansson J, Mölgaard J, Olsson AG: Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia. Atherosclerosis 1991, 91: 175–184.
  Article PubMed CAS Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al.: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98: 2088–2093.
  PubMed CAS Google Scholar
• Vu-Dac N, Schoonjans K, Kosykh V, et al.: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995, 96: 741–750.
  Article PubMed CAS Google Scholar
• Asztalos BF, Horvath KV, McNamara JR, et al.: Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002, 43: 1701–1707.
  Article PubMed CAS Google Scholar
• Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323: 1289–1298.
  PubMed CAS Google Scholar
• Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345: 1583–1592.
  Article PubMed CAS Google Scholar
• Asztalos BF, Batista M, Horvath KV, et al.: Change in a1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23: 847–852.
  Article PubMed CAS Google Scholar
• Rubins HB, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341: 410–418.
  Article PubMed CAS Google Scholar
• Syvänne M, Nieminen MS, Frick MH, et al., for the Lopid Coronary Angiography Trial (LOCAT) Study Group: Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998, 98: 1993–1999.
  PubMed Google Scholar
• Ruotolo G, Ericsson CG, Tettamanti C, et al.: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32: 1648–1656.
  Article PubMed CAS Google Scholar
• Krause BR, Auerbach BJ: Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Invest Drug 2001, 2: 375–381.
  CAS Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290: 2292–2300.
  Article PubMed CAS Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350: 1505–1515.
  Article PubMed CAS Google Scholar
• Rittershaus CW, Miller DP, Thomas LJ, et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20: 2106–2112.
  PubMed CAS Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23: 160–167.
  Article PubMed CAS Google Scholar